Shots:
- The US FDA has approved Kerendia (finerenone, 10 & 20mg) for the treatment of adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D)
- Approval was supported by the global P-III (FINE-ONE) trial assessing Kerendia (10 or 20mg, QD) + SoC vs PBO in 242 pts with CKD associated with T1D
- Kerendia + SoC reduced UACR by 25% over 6mos. (1EP); UACR reduction was 22% & 28% at 3 & 6mos., respectively. Additionally, at any time post-baseline, 68.1% pts achieved ≥30% UACR reduction vs 46.6%; data were published in The NEJM
Ref: Bayer | Image: Bayer | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
